GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tilray Brands Inc (TSX:TLRY) » Definitions » Beta

Tilray Brands (TSX:TLRY) Beta : 3.31 (As of May. 01, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Tilray Brands Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-05-01), Tilray Brands's Beta is 3.31.


Tilray Brands Beta Historical Data

The historical data trend for Tilray Brands's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tilray Brands Beta Chart

Tilray Brands Annual Data
Trend Aug14 May15 May16 May17 May18 May19 May20 May21 May22 May23
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.02 1.84 2.24 2.15 3.94

Tilray Brands Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.54 3.94 3.98 3.07 3.08

Competitive Comparison of Tilray Brands's Beta

For the Drug Manufacturers - Specialty & Generic subindustry, Tilray Brands's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tilray Brands's Beta Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tilray Brands's Beta distribution charts can be found below:

* The bar in red indicates where Tilray Brands's Beta falls into.



Tilray Brands Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.


Tilray Brands  (TSX:TLRY) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Tilray Brands Beta Related Terms

Thank you for viewing the detailed overview of Tilray Brands's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.


Tilray Brands (TSX:TLRY) Business Description

Traded in Other Exchanges
Address
265 Talbot Street West, Leamington, ON, CAN, N8H 5L4
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. U.S. exposure consists of CBD products and alcohol.